financetom
Business
financetom
/
Business
/
SentinelOne Insider Sold Shares Worth $3,170,403, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SentinelOne Insider Sold Shares Worth $3,170,403, According to a Recent SEC Filing
Feb 14, 2025 12:50 AM

03:24 AM EST, 02/14/2025 (MT Newswires) -- Tomer Weingarten, Director, President, Chief Executive Officer, on February 11, 2025, sold 131,506 shares in SentinelOne ( S ) for $3,170,403. Following the Form 4 filing with the SEC, Weingarten has control over a total of 939,726 Class A common shares of the company, with 939,726 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1583708/000158370825000015/xslF345X05/wk-form4_1739499029.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Heritage Commerce's Board Approves $15 Million Share Repurchase Program
Heritage Commerce's Board Approves $15 Million Share Repurchase Program
Jul 26, 2024
05:23 AM EDT, 07/26/2024 (MT Newswires) -- Heritage Commerce ( HTBK ) said late Thursday its board has approved a $15 million share repurchase program. The program is set to expire on July 31, 2025, unless suspended or terminated earlier. Price: 10.63, Change: -0.08, Percent Change: -0.75 ...
AbbVie Gets European Commission Marketing Authorization for Skyrizi to Treat Ulcerative Colitis
AbbVie Gets European Commission Marketing Authorization for Skyrizi to Treat Ulcerative Colitis
Jul 26, 2024
05:23 AM EDT, 07/26/2024 (MT Newswires) -- AbbVie ( ABBV ) said Friday the European Commission has approved Skyrizi for treating adult patients with moderately to severely active ulcerative colitis, a chronic inflammatory bowel disease. The marketing authorization for Skyrizi marks its fourth approved indication in the European Union, the company said. The medication is for patients who have had...
Calliditas Therapeutics Says Liver Disease Therapy Met Main Goal in Phase 2b Study
Calliditas Therapeutics Says Liver Disease Therapy Met Main Goal in Phase 2b Study
Jul 26, 2024
05:15 AM EDT, 07/26/2024 (MT Newswires) -- Calliditas Therapeutics ( CALT ) said Friday a phase 2b study of its setanaxib experimental therapy to treat patients with primary biliary cholangitis and elevated liver stiffness met its primary goal. In the study, patients treated with setanaxib showed statistically significant improvement in Alkaline Phosphatase for both doses tested compared with placebo, the...
Karooooo Terminates Secondary Public Offering Due to Market Conditions
Karooooo Terminates Secondary Public Offering Due to Market Conditions
Jul 26, 2024
05:18 AM EDT, 07/26/2024 (MT Newswires) -- Karooooo ( KARO ) said Friday Chief Executive Isaias Jose Calisto has terminated the secondary public offering of ordinary shares, first announced on July 24. The company said despite strong investor interest and oversubscription, Calisto decided to halt the offering due to recent market changes affecting the share price. As a result of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved